HUMAN CGRP RECEPTOR BINDING ANTIBODIES

(19)

(11)

EP 2 379 594 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	30.12.2020 Bulletin 2020/53

(45)	Mention of the grant of the patent:
	09.08.2017 Bulletin 2017/32

(21)	Application number: 09775072.3

(22)	Date of filing: 18.12.2009

(51)

International Patent Classification (IPC):

C07K 16/28^(2006.01)

C07K 14/72^(2006.01)

(86)	International application number:
	PCT/US2009/068858

(87)	International publication number:
	WO 2010/075238 (01.07.2010 Gazette 2010/26)

(54)	HUMAN CGRP RECEPTOR BINDING ANTIBODIES AN DEN HUMANEN CGRP-REZEPTOR BINDENDE ANTIKÖRPER ANTICORPS SE LIANT AU RÉCEPTEUR CGRP HUMAIN

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
	Designated Extension States:
	AL BA RS

(30)

Priority:

23.12.2008 US 203569 P
25.11.2009 US 264622 P

(43)	Date of publication of application:
	26.10.2011 Bulletin 2011/43

(60)	Divisional application:
	16199717.6 / 3184546
	19181187.6 / 3569620

(73)	Proprietor: Amgen Inc.
	Thousand Oaks, CA 91320-1799 (US)

(72)

Inventors:

BOONE, Thomas C.
Newbury Park California 91320 (US)
BRANKOW, David W.
Northridge California 91326 (US)
GEGG, JR., Colin V.
Newbury Park California 91320 (US)
HU, Shaw-Fen Sylvia
Thousand Oaks California 91360 (US)
KING, Chadwick T.
North Vancouver British Columbia V7L 3T5 (CA)
LU, Hsieng Sen
Westlake Village California 91362 (US)
SHI, Licheng
Newbury Park California 91320 (US)
XU, Cen
Newbury Park California 91320 (US)

(74)	Representative: Grünecker Patent- und Rechtsanwälte PartG mbB
	Leopoldstraße 4 80802 München 80802 München (DE)

(56)

References cited: :

WO-A1-2007/076336
WO-A2-2006/068953

WO-A1-2010/012911
US-A1- 2005 282 252

TAYLOR CHRISTOPHER K ET AL: "PHARMACOLOGICAL CHARACTERIZATION OF NOVEL ALPHA-CALCITONIN GENE-RELATED PEPTIDE (CGRP) RECEPTOR PEPTIDE ANTAGONISTS THAT ARE SELECTIVE FOR HUMAN CGRP RECEPTORS" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 319, no. 2, 1 November 2006 (2006-11-01), pages 749-757, XP009084228 ISSN: 0022-3565
DAVIS CARL D ET AL: "The Tortuous Road to an Ideal CGRP Function Blocker for the Treatment of Migraine" CURRENT TOPICS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD, NL, vol. 8, no. 16, 1 November 2008 (2008-11-01), pages 1468-1479, XP008119816 ISSN: 1568-0266
DURHAM PAUL L: "CGRP-RECEPTOR ANTAGONISTS--A FRESH APPROACH TO MIGRAINE THERAPY?" NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 350, no. 11, 11 March 2004 (2004-03-11), pages 1073-1075, XP009082423 ISSN: 1533-4406
CHAUHAN M ET AL: "Studies on the effects of the N-terminal domain antibodies of calcitonin receptor-like receptor and receptor activity-modifying protein 1 on calcitonin gene-related peptide-induced vasorelaxation in rat uterine artery." June 2004 (2004-06), BIOLOGY OF REPRODUCTION JUN 2004, VOL. 70, NR. 6, PAGE(S) 1658 - 1663 , XP002571487 ISSN: 0006-3363 the whole document

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).